The Randomized Aldactone Evaluation Study (RALES), a
|
|
- Madlyn Griffin
- 5 years ago
- Views:
Transcription
1 Limitation of Excessive Extracellular Matrix Turnover May Contribute to Survival Benefit of Spironolactone Therapy in Patients With Congestive Heart Failure Insights From the Randomized Aldactone Evaluation Study (RALES) Faiez Zannad, MD, PhD; François Alla, MD; Brigitte Dousset, MD, PhD; Alfonso Perez, MD; Bertram Pitt, MD; on behalf of the RALES Investigators Background In congestive heart failure (CHF), extracellular matrix turnover is a major determinant of cardiac remodeling. It has been suggested that spironolactone may decrease cardiac fibrosis. We investigated the interactions between serum markers of cardiac fibrosis and the effect of spironolactone on outcome in patients with CHF. Methods and Results A sample of 261 patients from the Randomized Aldactone Evaluation Study (RALES) were randomized to placebo or spironolactone (12.5 to 50 mg daily). Serum procollagen type I carboxy-terminal peptide, procollagen type I amino-terminal peptide, and procollagen type III amino-terminal peptide (PIIINP) were assessed at baseline and at 6 months. Baseline PIIINP 3.85 g/l was associated with an increased risk of death (relative risk [RR] 2.36, 95% CI 1.34 to 4.18) and of death hospitalization (RR 1.83, 95% CI 1.18 to 2.83). At 6 months, markers decreased in the spironolactone group but remained unchanged in the placebo group. The spironolactone effect on outcome was significant only in patients with above-median baseline levels of markers. RR (95% CI) values for death among patients receiving spironolactone were 0.44 (0.26 to 0.75) and 1.11 (0.66 to 1.88) in subgroups of PIIINP levels above and below the median, respectively. Similarly, RR (95% CI) values for death hospitalization among patients receiving spironolactone were 0.45 (0.29 to 0.71) and 0.85 (0.55 to 1.33), respectively. Conclusions In patients with CHF, high baseline serum levels of markers of cardiac fibrosis synthesis are significantly associated with poor outcome and decrease during spironolactone therapy. The benefit from spironolactone was associated with higher levels of collagen synthesis markers. These results suggest that limitation of the excessive extracellular matrix turnover may be one of the various extrarenal mechanisms contributing to the beneficial effect of spironolactone in patients with CHF. (Circulation. 2000;102: ) Key Words: heart failure collagen tissue hormones trials The Randomized Aldactone Evaluation Study (RALES), a placebo-controlled randomized trial, has demonstrated that the blockade of aldosterone receptors by spironolactone (25 mg daily), in addition to standard therapy including ACE inhibitors, significantly reduces the risk of both morbidity and death among patients with severe congestive heart failure (CHF) due to left ventricular systolic dysfunction. 1 The mechanism of these beneficial effects is uncertain. Spironolactone may be effective because it opposes the effects of aldosterone on sodium retention, loss of magnesium and potassium, sympathetic activation, parasympathetic inhibition, baroreceptor function, vascular damage, and/or arterial compliance. 2 4 Spironolactone may also oppose the effect of aldosterone in promoting cardiac fibrosis. 5 7 Extracellular matrix (ECM) turnover is an essential process found in cardiac remodeling in hypertensive cardiac hypertrophy, in dilated cardiomyopathy, and after myocardial infarction. 8 Cardiac fibrosis is a major determinant of diastolic function and pumping capacity, and it may provide the structural substrate for arrhythmogenicity, 8 thus potentially contributing to the progression of heart failure and to sudden death. Measurement of cardiac collagen turnover by use of serological markers is a useful tool for monitoring cardiac tissue repair and fibrosis 9 in experimental models 10 and in clinical conditions The purpose of the present study was to examine, in a subgroup of patients with CHF randomized in the RALES trial, the value of these serological markers for cardiac ECM turnover as prognostic predictors of death and hospitalization, as well as the effects of spironolactone on these markers and Received May 18, 2000; revision received July 11, 2000; accepted July 14, From the Centre d Investigation Clinique INSERM-CHU (F.Z., F.A.) and the Laboratory of Biochemistry (B.D.), Centre Hospitalier Universitaire, University Henri Poincaré, Nancy, France; Searle Monsanto (A.P), Skokie, Ill; and the Department of Internal Medicine (B.P.), Division of Cardiology, University of Michigan, Ann Arbor. Dr Alfonso Perez is an employee of Searle. Correspondence to Prof Faiez Zannad, Centre d Investigation Clinique INSERM-CHU, Hôpital Jeanne d Arc, Toul, France. cic@chu-nancy.fr 2000 American Heart Association, Inc. Circulation is available at
2 Zannad et al Spironolactone and Cardiac Fibrosis in CHF 2701 the interaction between spironolactone-induced changes of these markers with morbidity and mortality. Methods Patients and Study Design A sample of 261 patients randomized in French centers into the RALES trial 1 participated in this substudy. RALES included patients with severe chronic heart failure (history of New York Heart Association [NYHA] class IV within 6 months and NYHA class III or IV at randomization, left ventricular ejection fraction 35%). Patients were randomized to placebo or spironolactone (12.5 to 50 mg daily) added to conventional therapy. Laboratory Analysis Blood samples were drawn at baseline and 6 months after randomization. Serum samples were stored at 20 C until assay. All baseline and 6-month follow-up samples were analyzed at once. Technicians were blinded to the order of the sample. No changes were observed in the samples analyzed twice. Using a radioimmunoassay from commercially available kits (Orion Diagnostica), we measured 3 ECM serum markers: procollagen type III aminoterminal peptide (PIIINP), procollagen type I carboxy-terminal peptide (PICP), and procollagen type I amino-terminal peptide (PINP). Determination of 3 degradation markers (total membrane metalloproteinase 1 [MMP1], total tissue inhibitor of metalloproteinase 1 [TIMP1], and the MMP1/TIMP1 complex) was performed by ELISA kits (Amersham). The serum levels of free MMP1 and free TIMP1 were calculated after subtracting the values of the MMP1/ TIMP1 complex from the values of total MMP1 and total TIMP1, respectively. Interassay and intra-assay variations ranged from 3% to 13% for all variables. The sensitivity (lowest concentration different from zero) was 0.2 ng/ml for PIIINP, 2.0 ng/ml for PINP, 1.2 ng/ml for PICP, 1.7 ng/ml for MMP1, 1.2 ng/ml for TIMP1, and 1.5 ng/ml for the MMP1/TIMP1 complex Data Collection Baseline variables collected at the time of randomization consisted of the following: sociodemographic (age, sex, and race), clinical (etiology, NYHA class, weight, heart rate, and blood pressure), chronic degenerative comorbidity (bone or joint disease, such as rheumatoid arthritis, arthropathy, osteoporosis, and multiple myeloma; other fibrotic disease, such as various cancers, renal failure, pulmonary fibrosis, and liver cirrhosis; and diabetes), laboratory (serum sodium, serum potassium, and serum creatinine), hemodynamic (left ventricular ejection fraction), and concomitant medication data (diuretics, ACE inhibitors, -blockers, digitalis, aspirin, potassium supplement, calcium blockers, and corticoids) (Table 1). The survival follow-up period extended from the day of randomization to the end-point date of August 24, Mean follow-up was 24 months. Statistical Analysis Statistical analysis consisted of (1) a descriptive analysis (values are expressed as mean SD), (2) a study of association between baseline characteristics and baseline ECM turnover serum markers values, (3) a study of serum marker changes from baseline to 6 months (ANOVA with repeated-measures models), (4) an evaluation of baseline serum markers as predictors of survival and CHF hospitalization free survival, 1 and (5) testing the relationship between baseline ECM turnover serum markers levels and survival benefit from spironolactone. For intergroup comparisons, we used ad hoc methods (univariate analysis, such as Pearson 2 test, Mann-Whitney test, ANOVA, or correlation; multivariate analysis, such as the multiple linear regression model or the logistic regression model). Survival rates and CHF hospitalization free survival rates were estimated by use of Kaplan- Meier analyses. All variables listed above were tested with respect to their relation to survival and CHF hospitalization free survival by use of a univariate Mantel-Cox analysis. Variables significantly related to survival or CHF hospitalization free survival were entered into a Cox TABLE 1. Patients Baseline Characteristics Placebo (n 133) Spironolactone (n 129) Age, y Male, % White, % Ischemic etiology, % LV ejection fraction, % NYHA class (III/IV),* % 79/21 72/28 Weight, kg Systolic blood pressure, mm Hg Diastolic blood pressure, mm Hg Serum sodium, mmol/l Serum creatinine, mol/l Diabetes, % Chronic degenerative disease, % 11 7 Drug therapy at baseline Diuretics, % Furosemide, % Daily dose, mg Digitalis, % Aspirin, % Potassium supplements, % Blockers, % 5 5 Calcium blockers, % 8 11 ACE inhibitors, % Corticoids, % 8 10 Values are mean SD or as indicated. *Four patients (2 placebo and 2 spironolactone) were in class II at time of randomization. multivariate model, adjusted for other prognostic variables. Associations between markers and survival or CHF hospitalization free survival for each randomization group were analyzed in 3 different ways, ie, by using marker values as a continuous variable, as a categorical variable with a cutoff value as the median of distribution, and after a receiver operating characteristic like analysis. All analyses were performed by use of BMDP software version 7.0 (1993). Results Of the 261 patients included in the present study, 133 were in the placebo group, and 129 were in the spironolactone group. Mean age, sex, etiology, left ventricular ejection fraction, and cardiovascular drug therapy at baseline were similar in both groups (Table 1). Diabetes tended to be more frequent in the placebo group; however, this was not statistically significant (P 0.054). Baseline Levels of ECM Turnover Markers In the whole population sample of 261 patients, baseline levels (mean SD) were g/l for PIIINP, g/l for PICP, g/l for PINP, g/l for free MMP1, and g/l for free TIMP1. There was no difference in mean baseline levels between the placebo and the spironolactone groups (Table 2). Patients with chronic degenerative disease (bone disease,
3 2702 Circulation November 28, 2000 TABLE 2. Serum Levels of Cardiac ECM Markers at Randomization and at 6 mo Baseline 6 mo Change (6-mo Baseline) P * (Spironolactone vs Placebo) P * (Spironolactone vs Placebo) Absolute Difference P (Baseline vs 6 mo) P (Spironolactone vs Placebo) n Mean SD Mean SD PIINP, g/l Spironolactone Placebo NS NS PICP, g/l Spironolactone NS Placebo NS NS 13.1 NS 0.07 PINP, g/l Spironolactone Placebo NS NS 0.02 Free MMP1, g/l Spironolactone NS Placebo NS NS 0.09 NS NS Free TIMP1, g/l Spironolactone NS Placebo NS NS NS NS For spironolactone vs placebo, P NS (Pearson 2 for categorical variables, Mann-Whitney for continuous variables). *Student t test. Matched t test. ANOVA adjusted by baseline values. other inflammations, and diabetes) had significantly higher baseline levels of 1 collagen serum marker. Multivariate analysis showed that neither sex nor baseline NYHA class nor left ventricular ejection fraction (Figure 1) affected baseline ECM turnover markers. For example, baseline PII- INP was 4.9 g/l in NYHA class III patients and 5.1 g/l in class IV patients (P 0.71). These values were 4.7 and 5.1 g/l, respectively, in patients with a baseline furosemide dose below and above median (60 mg) (P 0.21). However, ischemic heart disease (5.3 versus 4.7 g/l for ischemic versus nonischemic, P 0.02) and baseline treatment with digoxin (4.7 versus 5.4 g/l for on digoxin versus off digoxin, P 0.001) were independently associated with baseline PIIINP levels. Figure 1. Scatterplot between PIIINP and LV ejection fraction at baseline. Baseline to 6-Month Changes In 111 patients, a blood sample could not be obtained at 6 months (36 deaths and 75 missing samples). In 151 patients, serum ECM markers could be assessed both at baseline and 6 months after randomization (36 deaths, 75 missing samples). Their baseline characteristics (including ECM turnover marker levels) did not differ from those of the initial group of patients. From baseline to 6 months, PINP and PIIINP decreased only in the spironolactone group. We analyzed changes in markers in subgroups with high (above-median) and low (below-median) levels. When PICP, PINP, and PIIINP baseline levels were above median, they did not change significantly over 6 months in the placebo group, but they decreased significantly in the spironolactone group (Figure 2). Free MMP1 and free TIMP1 levels did not change over the 6-month follow-up period in either treatment group. Prognostic Significance Overall, survival and CHF hospitalization free survival were poor (1-year rates were 74.6% and 57.3%, respectively) and were higher in the spironolactone group than in the placebo group (76.6% and 63.3% versus 72.7% and 51.5%, respectively). Because there was a significant interaction among baseline ECM turnover markers, treatment groups, and outcome, analysis of the prognostic significance of ECM turnover markers was performed separately in the placebo and the spironolactone groups. Baseline PIIINP, with a cutoff value (receiver operating characteristic analysis) of 3.85 g/l, had a significant independent negative correlation with survival and CHF hospitalization free survival in the placebo group. Patients with
4 Zannad et al Spironolactone and Cardiac Fibrosis in CHF 2703 Figure 2. Top, Changes of serum markers of ECM turnover from baseline to 6 months (in micrograms per liter). Bottom, Changes of serum levels of PIIINP from baseline to 6 months according to baseline levels above or below median (in micrograms per liter). baseline PIIINP 3.85 g/l, compared with patients with PIIINP 3.85 g/l, had a relative risk of death of 2.36 (95% CI 1.34 to 4.18, P 0.003) and a relative risk of death and/or CHF hospitalization of 1.83 (95% CI 1.18 to 2.83, P 0.007). In the 81 patients (61.8%) with baseline PIIINP levels 3.85 g/l, survival and CHF hospitalization free survival were 69.1% and 44.3%, respectively, compared with 79.6% and 63.4%, respectively, in the remaining 50 patients with levels
5 2704 Circulation November 28, 2000 Figure 3. Kaplan-Meier survival according to PIIINP baseline levels (placebo group) g/l (Figure 3). In contrast, in the spironolactone group, baseline PIIINP levels were not associated with survival or with CHF hospitalization free survival. When the median value is considered as a cutoff point, the results were similar (Figure 4). Reduction of Risk of Death and of Risk of Death or CHF Hospitalization With Spironolactone According to Baseline Levels of ECM Turnover Markers In the RALES main study, the reduction of the risk of death among patients in the spironolactone group was 30% overall. This result was similar in all prespecified and retrospective analyses performed according to age, left ventricular ejection fraction, cause of heart failure, median creatinine, median potassium, use of digitalis, ACE inhibitors, and -blockers, and sex. 1 In the present substudy, analyzing the data according to baseline ECM turnover markers revealed that the survival benefit was most predominant in subgroups with PICP, PINP, and PIIINP baseline levels above median (Figures 4 and 5). Analyses of the effect on death and/or hospitalization revealed similar results (Table 3). Discussion We found that high serum levels of several markers for cardiac fibrosis in patients with CHF receiving conventional Figure 4. Thirty-month mortality according to treatment groups and PIIINP baseline levels (below/above median [med]). Figure 5. Adjusted relative risk of death from all causes and according to baseline serum levels of ECM turnover markers. Horizontal lines indicate 95% CIs. therapy, including ACE inhibitors, were associated with high mortality and hospitalization rates. In patients randomized to placebo, markers continued to increase or remained unchanged after a 6-month follow-up. On the contrary, adding spironolactone (25 mg daily) significantly decreased the levels of these serum markers during the same follow-up period. Most important, the spironolactone-related morbidity and mortality benefit was most predominant in subgroups with the highest baseline levels of PICP, PINP, and PIIINP. There is now accumulating evidence to show that serum levels of procollagen peptide fragments and of metalloproteinases can be used as markers for cardiac collagen turnover. PIIINP is the most frequently studied marker. Collagen scar formation after acute myocardial infarction causing left ventricular dysfunction could be quantified by measurements of serum PIIINP concentrations. 11 PIIINP levels are also raised chronically in patients with hypertensive left ventricular hypertrophy as well as in patients with dilated cardiomyopathy. The average baseline levels of PIIINP in our patients were similar to average baseline levels reported in patients after acute myocardial infarction ( g/l) 11 and in patients with CHF due to dilated cardiomyopathy ( g/l) 14 receiving conventional therapy, including ACE inhibitors. The validation of the studied serum markers as indicators of cardiac ECM turnover has been reported in experimental models. 19,21 24 Because intact PINP, PICP, and PIIINP are liberated during collagen biosynthesis, it is possible to use them as markers of this process. 9,25,26 Recently, Querejeta et al 16 showed a strong correlation between myocardial collagen content and the serum concentration of PICP in hypertensive patients. Changes in PIIINP have been shown to be induced by acute myocardial infarction in humans 13 and may reflect both synthesis and degradation of collagen. 27 Elevated baseline levels of synthesis markers in our CHF patients and, most important, in the ischemic CHF subgroup for PIIINP are consistent with the concept of fibrosis being a dynamic tissue, as reviewed by Sun and Weber. 28 According to this concept, collagen synthesis is an ongoing process involving a persistent population of metabolically active myofibroblasts nourished by a neovasculature. This is in contrast to previous concepts of fibrous tissue as acellular inert tissue. Indeed, active myofibroblasts may be found in the infarcted human heart as late as 17 years after acute myocardial infarction, 29 and type I collagen mrna expression could still be increased
6 Zannad et al Spironolactone and Cardiac Fibrosis in CHF 2705 TABLE 3. Adjusted Relative Risk of Death and of Death or Hospitalization (Spironolactone vs Placebo), According to Baseline Serum Level of PIIINP PIIINP Median PIIINP Median RR (95% CI) P RR (95% CI) P Death 0.44 ( ) ( ) 0.70 Death or hospitalization 0.45 ( ) ( ) 0.48 in the infarcted rat heart as late as 90 days after myocardial infarction. 30 Prognostic Significance of Serum Levels of ECM Turnover In patients with acute myocardial infarction, PICP, PINP, and PIIINP serum levels were shown to be correlated with infarct size, left ventricular dysfunction, and the presence of coronary artery occlusion. 11 In another study, PIIINP levels on admission and for the few days after acute myocardial infarction were found to be higher in patients with poor outcome. 13 In patients with CHF from idiopathic or ischemic dilated cardiomyopathy, serum PIIINP levels were independent predictors of mortality. 14 Our results confirm the prognostic value of PIIINP serum levels in a large group of patients with CHF receiving conventional therapy, including an ACE inhibitor. All 3 markers were independently associated with an increased risk of death. Furthermore, our results are the first to describe a correlation between these markers and the risk of hospitalization for heart failure. Interestingly, patients with ischemic heart disease had higher levels of PIIINP than did patients with CHF of a nonischemic cause. This may be a further indication of the prognostic value of PIIINP, inasmuch as mortality is usually higher in patients with CHF of an ischemic origin. 31 On the other hand, we found that patients chronically treated with digitalis had a lower level of PIIINP. This is consistent with the finding that digoxin reduces death due to the progression of heart failure. 32 Factors involved in collagen degradation (MMP1 and TIMP1) were not associated with the risk of death. It may be that ECM turnover in CHF is more directed to a higher synthesis rate, as assessed by the concentrations of circulating procollagen peptides, than to an altered collagen degradation. Also, other degradation products may be more relevant and need further investigation. The rate-limiting step in the extracellular degradation of collagen is MMP1, which accounts for the degradation of up to 40% of the newly synthesized collagen in different tissues. 33 The net level of MMP1 activity is dependent on the relative concentrations of active enzyme and a family of naturally occurring tissue inhibitors of metalloproteinases, namely, TIMP1. 34 To our knowledge, there is no clinical report of free MMP1 and free TIMP1 assessment in patients with heart failure or acute myocardial infarction. Effects of Spironolactone on Serum Levels of Collagen Markers Aldosterone has been shown to promote cardiac fibrosis in various experimental models. 7,35 37 The temporal cellular response and appearance of myocardial fibrosis associated with chronic elevation of angiotensin II and/or aldosterone differ, indicating that separate pathogenic mechanisms are operative with these effector hormones of the renin-angiotensinaldosterone system. 6 In several reports, it has been demonstrated that spironolactone may oppose the effect of aldosterone in promoting cardiac fibrosis. 5 7,38 In a small clinical study, a high dose of spironolactone (50 to 100 mg/d) produced a significant decrease of PIIINP serum levels in 21 patients with CHF. 39 Our results are the first to report a significant effect of a low dose of spironolactone (26 mg/d on average) on several serum markers of collagen and to relate this effect to survival benefit in a large group of patients. This finding may be interpreted as a result of the limitation by spironolactone of collagen synthesis in the failing heart. The regulation of the key enzyme of collagen degradation, MMP1, which has been identified in the heart, is largely unknown. MMP1 activity in a cultured cardiac fibroblast preparation was not influenced by aldosterone. 40 Because collagen accumulation in the myocardium represents the balance between collagen synthesis and degradation, aldosterone appears to lead to a net accumulation of collagen, which is inhibited by spironolactone. The effects of spironolactone on collagen synthesis were most predominant in patients with the highest above-median baseline levels of PIIINP. Relationship Between Effects of Spironolactone on Collagen Markers and on Patients Outcomes In the present study, retrospective subgroup analysis showed that the beneficial effects of spironolactone on survival and hospital admission were almost primarily clustered within the subgroup of patients with the highest pretreatment levels of PICP, PINP, or PIIINP. All other prespecified and retrospective subgroup analyses in the main RALES 1 failed to characterize any demographic, clinical, or laboratory variable that would influence the clinical benefit of spironolactone therapy. The demonstrated prognostic importance of serum levels of the collagen markers in the present study and the significant decrease of these levels in the spironolactone treated group of patients strongly suggest that limitation of the aldosterone-stimulated collagen synthesis may be one of the various extrarenal mechanisms contributing to the clinical benefit of spironolactone in the RALES trial. Limitation of the Present Study Some limitations of the present study should be acknowledged. This substudy was performed in a subset of patients from the RALES trial. Although the major characteristics of our patients were comparable to those of the overall RALES patient population, extrapolation of our results to all patients in the trial should be made with caution.
7 2706 Circulation November 28, 2000 Blood samples at the 6-month follow-up could not be obtained from all patients in the substudy because of missing samples and early deaths. However, the changes of the serum levels of collagen markers over 6 months were analyzed by paired data analysis, ie, analysis only in patients with available baseline and 6-month data. The interaction analysis between baseline markers levels, treatment group, and outcome was a retrospective analysis in nonprespecified subgroups. Therefore, one cannot exclude that our result may be a chance finding. Nevertheless, we believe that the coherence of the results of analyses of the prognostic values of serum markers and their respective congruent change over time in the spironolactone group and the placebo group give credit to the main result of the interaction analysis. Conclusions For the first time, we observe that serum levels of markers of cardiac collagen synthesis were significantly associated with poor outcome in patients with CHF and could be decreased by aldosterone receptor blockade with spironolactone. The morbidity and mortality benefit from spironolactone is predominant in patients with the highest levels of markers. These results, which require further prospective confirmation, suggest that limitation of the aldosterone-related excessive ECM turnover may be one of the various extrarenal mechanisms contributing to the beneficial effect of spironolactone in patients with CHF. References 1. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with sever heart failure: Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341: Weber KT. Aldosterone and spironolactone in heart failure. N Engl J Med. 1999;341: Zannad F. Angiotensin-converting enzyme inhibitor and spironolactone combination therapy: new objectives in congestive heart failure treatment. Am J Cardiol. 1993;71:34A 39A. 4. Zannad F. Aldosterone and heart failure. Eur Heart J. 1995;16(suppl): Brilla CG, Matsubara LS, Weber KT. Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J Mol Cell Cardiol. 1993;25: Lijnen P, Petrov V. Antagonism of the renin-angiotensin-aldosterone system and collagen metabolism in cardiac fibroblasts. Methods Find Exp Clin Pharmacol. 1999;21: Fullerton MJ, Funder JW. Aldosterone and cardiac fibrosis: in vitro studies. Cardiovasc Res. 2000;1994: Swynghedauw B. Molecular mechanisms of myocardial remodeling. Physiol Rev. 1999;79: Weber KT. Monitoring tissue repair and fibrosis from a distance. Circulation. 1997;96: Laviades C, Varo N, Fernandez J, et al. Abnormalities of the extracellular degradation of collagen type I in essential hypertension. Circulation. 1998;98: Uusimaa P, Risteli J, Niemela M, et al. Collagen scar formation after acute myocardial infarction: relationships to infarct size, left ventricular function, and coronary artery patency. Circulation. 1997;96: Sato Y, Kataoka K, Matsumori A, et al. Measuring serum aminoterminal type III procollagen peptide, 7S domain of type IV collagen, and cardiac troponin T in patients with idiopathic dilated cardiomyopathy and secondary cardiomyopathy. Heart. 1997;78: Host NB, Jensen LT, Bendixen PM, et al. The aminoterminal propeptide of type III procollagen provides new information on prognosis after acute myocardial infarction. Am J Cardiol. 1995;76: Klappacher G, Franzen P, Haab D, et al. Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosis. Am J Cardiol. 1995;75: Diez J, Laviades C, Mayor G, et al. Increased serum concentration of procollagen peptides in essential hypertension: relation to cardiac alteration. Circulation. 1995;91: Querejeta R, Varo N, Lopez B, et al. Serum carboxy-terminal propeptide of procollagen type I is a marker of myocardial fibrosis in hypertensive heart disease. Circulation. 2000;201: Lein M, Nowak L, Jung K, et al. Analytical aspects regarding the measurement of metalloproteinases and their inhibitors in blood. Clin Biochem. 1997;30: Melkko J, Kauppila S, Niemi S, et al. Immunoassay for intact amino-terminal propeptide of human type I procollagen. Clin Chem. 1996;42: Melkko J, Niemi S, Risteli L, et al. Radioimmunoassay of the carboxyterminal propeptide of human type I procollagen. Clin Chem. 1990;36: Risteli J, Niemi S, Trivedi P, et al. Rapid equilibrium radioimmunoassay for the amino-terminal propeptide of human type III procollagen. Clin Chem. 1988;34: Diez J, Laviades C. Monitoring fibrillar collagen turnover in hypertensive heart disease. Cardiovasc Res. 1997;35: Diez J, Panizo A, Gil MJ, et al. Serum markers of collagen type I metabolism in spontaneously hypertensive rats. Circulation. 1996;93: Sekita S, Katagiri T, Sasai Y, et al. Studies on collagen in the experimental myocardial infarction. Jpn Circ J. 1985;49: Whittaker P, Boughner DR, Kloner RA. Analysis of healing after myocardial infarction using polarized light microscopy. Am J Pathol. 1989; 134: Risteli J, Risteli L. Analysing connective tissue metabolites in human serum: biochemical, physiological and methodological aspects. J Hepatol. 1995;22(suppl 2): Jensen LT, Horslev-Petersen K, Toft P, et al. Serum aminoterminal type III procollagen peptide reflects repair after myocardial infarction. Circulation. 1990;81: Peuhkurinen KJ, Risteli L, Melkko J, et al. Thrombolytic therapy with streptokinase stimulates collagen breakdown. Circulation. 1991;83: Sun Y, Weber KT. Infarct scar: a dynamic tissue. Cardiovasc Res. 2000;46: Willems IE, Havenith MG, De Mey JG, et al. The alpha-smooth muscle actin-positive cells in healing human myocardial scars. Am J Pathol. 1994;145: Cleutjens JP, Verluyten MJ, Smiths JF, et al. Collagen remodeling after myocardial infarction in the rat heart. Am J Pathol. 1995;147: Zannad F, Briancon S, Juilliere Y, et al. Incidence, clinical and etiologic features, and outcomes of advanced chronic heart failure: the EPICAL Study: Epidémiologie de l Insuffisance Cardiaque Avancée en Lorraine. J Am Coll Cardiol. 1999;34: Yusuf S. Digoxin in heart failure: results of the recent Digoxin Investigation Group trial in the context of other treatments for heart failure. Eur Heart J. 1997;18: Woessner JF Jr. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J. 1991;5: Denhardt DT, Feng B, Edwards DR, et al. Tissue inhibitor of metalloproteinases (TIMP, aka EPA): structure, control of expression and biological functions. Pharmacol Ther. 1993;59: Campbell SE, Janicki JS, Weber KT. Temporal differences in fibroblast proliferation and phenotype expression in response to chronic administration of angiotensin II or aldosterone. J Mol Cell Cardiol. 1995;27: Robert V, Van TN, Cheav SL, et al. Increased cardiac types I and III collagen mrnas in aldosterone-salt hypertension. Hypertension. 1994;24: Young M, Fullerton MJ, Dilley R, et al. Mineralocorticoids, hypertension and cardiac fibrosis. J Clin Invest. 1994;93: Brilla CG, Weber KT. Mineralocorticoid excess, dietary sodium and myocardial fibrosis. J Lab Clin Med. 1992;120: MacFadyen RJ, Barr CS, Struthers AD. Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. Cardiovasc Res. 1997;35: Brilla CG, Maisch B, Weber K. Renin-angiotensin system and myocardial collagen matrix remodeling in hypertensive heart disease: in vivo and in vitro studies on collagen matrix regulation. Clin Invest. 1993;71: S35 S41.
Position Statement on ALDOSTERONE ANTAGONIST THERAPY IN CHRONIC HEART FAILURE
Position Statement on ALDOSTERONE ANTAGONIST THERAPY IN CHRONIC HEART FAILURE Over 8,000 patients have been studied in two well-designed placebo-controlled outcome-driven clinical trials to evaluate the
More informationStratification of heart failure using biomarkers of myocardial fibrosis
Stratification of heart failure using biomarkers of myocardial fibrosis Thesis Master Biology of Disease University of Utrecht Sanne de Jong 0476773 Supervisor: Dr. H.V.M. van Rijen University Medical
More informationAcute myocardial infarction (AMI) is an important medical. Heart Failure
Heart Failure Extracellular Cardiac Matrix Biomarkers in Patients With Acute Myocardial Infarction Complicated by Left Ventricular Dysfunction and Heart Failure Insights From the Eplerenone Post Acute
More informationAldosterone Antagonism in Heart Failure: Now for all Patients?
Aldosterone Antagonism in Heart Failure: Now for all Patients? Inder Anand, MD, FRCP, D Phil (Oxon.) Professor of Medicine, University of Minnesota, Director Heart Failure Program, VA Medical Center 111C
More informationBeneficial Neurohormonal Profile of Spironolactone in Severe Congestive Heart Failure Results From the RALES Neurohormonal Substudy
Journal of the American College of Cardiology Vol. 40, No. 9, 2002 2002 by the American College of Cardiology Foundation ISSN 0735-1097/02/$22.00 Published by Elsevier Science Inc. PII S0735-1097(02)02382-3
More informationAntialdosterone treatment in heart failure
Update on the Treatment of Chronic Heart Failure 2012 Antialdosterone treatment in heart failure 전남의대윤현주 Chronic Heart Failure Prognosis of Heart failure Cecil, Text book of Internal Medicine, 22 th edition
More informationThe benefit of treatment with -blockers in heart failure is
Heart Rate and Cardiac Rhythm Relationships With Bisoprolol Benefit in Chronic Heart Failure in CIBIS II Trial Philippe Lechat, MD, PhD; Jean-Sébastien Hulot, MD; Sylvie Escolano, MD, PhD; Alain Mallet,
More informationMedical management of LV aneurysm and subsequent cardiac remodeling: is it enough? J. Parissis Attikon University Hospital Athens, Greece
Medical management of LV aneurysm and subsequent cardiac remodeling: is it enough? J. Parissis Attikon University Hospital Athens, Greece Disclosures Grants: ALARM investigator received research grants
More informationΚΑΡΔΙΑΚΗ ΑΝΕΠΑΡΚΕΙΑ ΚΑΙ ΑΝΤΑΓΩΝΙΣΤΕΣ ΑΛΔΟΣΤΕΡΟΝΗΣ ΣΠΥΡΟΜΗΤΡΟΣ ΓΕΩΡΓΙΟΣ MD, FESC. E.Α Κ/Δ Γ.Ν.ΚΑΤΕΡΙΝΗΣ
ΚΑΡΔΙΑΚΗ ΑΝΕΠΑΡΚΕΙΑ ΚΑΙ ΑΝΤΑΓΩΝΙΣΤΕΣ ΑΛΔΟΣΤΕΡΟΝΗΣ ΣΠΥΡΟΜΗΤΡΟΣ ΓΕΩΡΓΙΟΣ MD, FESC. E.Α Κ/Δ Γ.Ν.ΚΑΤΕΡΙΝΗΣ Aldosterone is a mineralocorticoid hormone synthesized by the adrenal glands that has several regulatory
More informationDECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST TAKE HOME MESSAGES FROM RECENT HEART FAILURE CLINICAL TRIALS How to use aldosterone blockers? Faiez Zannad INSERM, U961 and Clinical Investigation Center CHU, Heart
More informationDr. Khairy Abdel Dayem. Professor of Cardiology Ain-Shams University
Dr. Khairy Abdel Dayem Professor of Cardiology Ain-Shams University RALES Randomized Aldactone Evaluation Study 1. NEJM 1999 2. Bertram Pitt 3. 1660 Class III and IV HF patients 4. EF 35% 5. 841 placebo
More informationManabu KOLA, and Kikuo ARAKAWA
317 Original Article The Regression of Left Ventricular Hypertrophy by Imidapril and the Reduction of Serum Procollagen Type III Amino-Terminal Peptide in Hypertensive Patients Manabu SASAGURI, Keita NODA,
More informationHeart Failure (HF) Treatment
Heart Failure (HF) Treatment Heart Failure (HF) Complex, progressive disorder. The heart is unable to pump sufficient blood to meet the needs of the body. Its cardinal symptoms are dyspnea, fatigue, and
More informationHeart Failure. Increased Collagen Type I Synthesis in Patients With Heart Failure of Hypertensive Origin. Relation to Myocardial Fibrosis
Heart Failure Increased Collagen Type I Synthesis in Patients With Heart Failure of Hypertensive Origin Relation to Myocardial Fibrosis Ramón Querejeta, MD, PhD*; Begoña López, PhD*; Arantxa González,
More informationI n patients with chronic heart failure caused by dilated
650 CARDIOVASCULAR MEDICINE Amino-terminal propeptide of type III procollagen is associated with restrictive mitral filling pattern in patients with dilated cardiomyopathy: a possible link between diastolic
More informationRisk Stratification in Heart Failure: The Role of Emerging Biomarkers
Risk Stratification in Heart Failure: The Role of Emerging Biomarkers David G. Grenache, PhD Associate Professor of Pathology, University of Utah Medical Director, ARUP Laboratories Salt Lake City, UT
More informationDrugs acting on the reninangiotensin-aldosterone
Drugs acting on the reninangiotensin-aldosterone system John McMurray Eugene Braunwald Scholar in Cardiovascular Diseases, Brigham and Women s Hospital, Boston & Visiting Professor, Harvard Medical School
More informationTherapeutic Targets and Interventions
Therapeutic Targets and Interventions Ali Valika, MD, FACC Advanced Heart Failure and Pulmonary Hypertension Advocate Medical Group Midwest Heart Foundation Disclosures: 1. Novartis: Speaker Honorarium
More informationDefinition of Congestive Heart Failure
Heart Failure Definition of Congestive Heart Failure A clinical syndrome of signs & symptoms resulting from the heart s inability to supply adequate tissue perfusion. CHF Epidemiology Affects 4.7 million
More informationHeart Failure: Combination Treatment Strategies
Heart Failure: Combination Treatment Strategies M. McDonald MD, FRCP State of the Heart Symposium May 28, 2011 None Disclosures Case 69 F, prior MIs (LV ejection fraction 25%), HTN No demonstrable ischemia
More informationOptimal blockade of the Renin- Angiotensin-Aldosterone. in chronic heart failure
Optimal blockade of the Renin- Angiotensin-Aldosterone Aldosterone- (RAA)-System in chronic heart failure Jan Östergren Department of Medicine Karolinska University Hospital Stockholm, Sweden Key Issues
More informationPathophysiology of heart failure with preserved ejection fraction. Extracellular matrix
Pathophysiology of heart failure with preserved ejection fraction Extracellular matrix Javier Díez, MD, PhD. Full Professor of Cardiovascular Medicine and Director Division of Cardiovascular Sciences Centre
More informationEvaluation of eplerenone in the subgroup of EPHESUS patients with baseline left ventricular ejection fraction 30%
The European Journal of Heart Failure 8 (2006) 295 301 www.elsevier.com/locate/ejheart Evaluation of eplerenone in the subgroup of EPHESUS patients with baseline left ventricular ejection fraction 30%
More informationJournal of the American College of Cardiology Vol. 35, No. 3, by the American College of Cardiology ISSN /00/$20.
Journal of the American College of Cardiology Vol. 35, No. 3, 2000 2000 by the American College of Cardiology ISSN 0735-1097/00/$20.00 Published by Elsevier Science Inc. PII S0735-1097(99)00608-7 The Prognostic
More informationMethods. Circ J 2007; 71:
Circ J 27; 71: 929 935 Serum Carboxy-Terminal Telopeptide of Type I Collagen (ICTP) Predicts Cardiac Events in Chronic Heart Failure Patients With Preserved Left Ventricular Systolic Function Tatsuro Kitahara,
More informationSatish K Surabhi, MD.FACC,FSCAI,RPVI Medical Director, Cardiac Cath Labs AnMed Health Heart & Vascular Care
Satish K Surabhi, MD.FACC,FSCAI,RPVI Medical Director, Cardiac Cath Labs AnMed Health Heart & Vascular Care None Fig. 1. Progression of Heart Failure.With each hospitalization for acute heart failure,
More informationOnline Appendix (JACC )
Beta blockers in Heart Failure Collaborative Group Online Appendix (JACC013117-0413) Heart rate, heart rhythm and prognostic effect of beta-blockers in heart failure: individual-patient data meta-analysis
More informationHypertrophic cardiomyopathy (HCM) is characterized by
Myocardial Collagen Turnover in Hypertrophic Cardiomyopathy Raffaella Lombardi, MD; Sandro Betocchi, MD; Maria Angela Losi, MD; Carlo Gabriele Tocchetti, MD; Mariano Aversa, MD; Marianna Miranda, MD; Gianluigi
More informationExtracellular Matrix Alterations in Patients With Paroxysmal and Persistent Atrial Fibrillation
Journal of the American College of Cardiology Vol. 52, No. 3, 2008 2008 by the American College of Cardiology Foundation ISSN 0735-1097/08/$34.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2008.03.045
More informationArbolishvili GN, Mareev VY Institute of Clinical Cardiology, Moscow, Russia
THE VALUE OF 24 H HEART RATE VARIABILITY IN PREDICTING THE MODE OF DEATH IN PATIENTS WITH HEART FAILURE AND SYSTOLIC DYSFUNCTION IN BETA-BLOCKING BLOCKING ERA Arbolishvili GN, Mareev VY Institute of Clinical
More informationInflammation in heart failure: biomarker, bystander or mediator
Inflammation in heart failure: biomarker, bystander or mediator Novel matricellular proteins to target Javier Díez, MD, PhD. Centre of Applied Medical Research and University Clinic School of Medicine,
More informationImprovement in collagen metabolism after 12 weeks cardiac resynchronization therapy in patients with ischaemic cardiomyopathy
Research Report Improvement in collagen metabolism after 12 weeks cardiac resynchronization therapy in patients with ischaemic cardiomyopathy Journal of International Medical Research 41(1) 200 207! The
More informationΧριστίνα Χρυσοχόου Καρδιολόγος Επι,Α Καρδιολογική Κλινική Πανεπιστηίου Αθηνών, ΙΓΝΑ
Χριστίνα Χρυσοχόου Καρδιολόγος Επι,Α Καρδιολογική Κλινική Πανεπιστηίου Αθηνών, ΙΓΝΑ Digitalisis a genus of about 20 species of herbaceousperennials, shrubs, and biennialsthat are commonly called foxgloves.
More informationIs spironolactone safe for dialysis patients?
Nephrol Dial Transplant (2003) 18: 2364 2368 DOI: 10.1093/ndt/gfg413 Original Article Is spironolactone safe for dialysis patients? Shahid Hussain 1, Darren E. Dreyfus 1, Richard J. Marcus 1, Robert W.
More informationThe clinical implications of aldosterone escape in congestive heart failure
The European Journal of Heart Failure 6 (2004) 539 545 www.elsevier.com/locate/heafai Review The clinical implications of aldosterone escape in congestive heart failure Allan D. Struthers* Division of
More informationCT for Myocardial Characterization of Cardiomyopathy. Byoung Wook Choi, Yonsei University Severance Hospital, Seoul, Korea
CT for Myocardial Characterization of Cardiomyopathy Byoung Wook Choi, Yonsei University Severance Hospital, Seoul, Korea Cardiomyopathy Elliott P et al. Eur Heart J 2008;29:270-276 The European Society
More informationNCAP NATIONAL CARDIAC AUDIT PROGR AMME NATIONAL HEART FAILURE AUDIT 2016/17 SUMMARY REPORT
NCAP NATIONAL CARDIAC AUDIT PROGR AMME NATIONAL HEART FAILURE AUDIT 2016/17 SUMMARY REPORT CONTENTS PATIENTS ADMITTED WITH HEART FAILURE...4 Demographics... 4 Trends in Symptoms... 4 Causes and Comorbidities
More informationNora Goldschlager, M.D. SFGH Division of Cardiology UCSF
CLASSIFICATION OF HEART FAILURE Nora Goldschlager, M.D. SFGH Division of Cardiology UCSF DISCLOSURES: NONE CLASSIFICATION C OF HEART FAILURE NYHA I IV New paradigm Stage A: Pts at high risk of developing
More informationDisclosures for Presenter
A Comparison of Angiotensin Receptor- Neprilysin Inhibition (ARNI) With ACE Inhibition in the Long-Term Treatment of Chronic Heart Failure With a Reduced Ejection Fraction Milton Packer, John J.V. McMurray,
More informationSerum BNP, hs-c-reactive protein, procollagen to assess the risk of ventricular tachycardia in ICD recipients after myocardial infarction
Europace (2007) 9, 724 729 doi:10.1093/europace/eum102 Serum BNP, hs-c-reactive protein, procollagen to assess the risk of ventricular tachycardia in ICD recipients after myocardial infarction Hugues Blangy
More informationRole of Aldosterone Antagonists in the Current Management of Heart Failure
Role of Aldosterone Antagonists in the Current Management of Heart Failure Yabluchansky, Nykola Chronic heart failure (HF) is one of the most important syndromes in cardiology. Their main causes are: ischemic
More informationDECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST Is there a mortality risk associated with aspirin use in heart failure? Results from a large community based cohort Margaret Bermingham, Mary-Kate Shanahan, Saki Miwa,
More informationRole of spironolactone in the treatment of heart failure with preserved ejection fraction
Review Article Page 1 of 5 Role of spironolactone in the treatment of heart failure with preserved ejection fraction Constantine E. Kosmas 1, Delia Silverio 2, Andreas Sourlas 3, Peter D. Montan 2, Eliscer
More informationCombination of renin-angiotensinaldosterone. how to choose?
Combination of renin-angiotensinaldosterone system inhibitors how to choose? Karl Swedberg Professor of Medicine Sahlgrenska Academy University of Gothenburg karl.swedberg@gu.se Disclosures Research grants
More informationThe Therapeutic Potential of Novel Approaches to RAAS. Professor of Medicine University of California, San Diego
The Therapeutic Potential of Novel Approaches to RAAS Inhibition in Heart Failure Barry Greenberg, M.D. Professor of Medicine University of California, San Diego Chain of Events Leading to End-Stage Heart
More informationeplerenone 25, 50mg film-coated tablets (Inspra ) SMC No. (793/12) Pfizer Ltd
eplerenone 25, 50mg film-coated tablets (Inspra ) SMC No. (793/12) Pfizer Ltd 08 June 2012 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards
More informationHeart failure with preserved ejection fraction (HFPEF) is
Relation of Peripheral Collagen Markers to Death and Hospitalization in Patients With Heart Failure and Preserved Ejection Fraction Results of the I-PRESERVE Collagen Substudy Henry Krum, MBBS, PhD, FRACP;
More informationHeart Failure. Acute. Plasma [NE] (pg/ml) 24 Hours. Chronic
Heart Failure Heart failure is the inability of the heart to deliver sufficient blood to the tissues to ensure adequate oxygen supply. Clinically it is characterized by signs of volume overload or symptoms
More informationEffects of heart rate reduction with ivabradine on left ventricular remodeling and function:
Systolic Heart failure treatment with the If inhibitor ivabradine Trial Effects of heart rate reduction with ivabradine on left ventricular remodeling and function: results of the SHIFT echocardiography
More informationA. Study Purpose and Rationale Background
A. Study Purpose and Rationale Background Congestive heart failure (CHF) affects roughly 6 million people in the United States with incidence rates rising steadily. Of even more concern, however, is the
More informationLCZ696 A First-in-Class Angiotensin Receptor Neprilysin Inhibitor
The Angiotensin Receptor Neprilysin Inhibitor LCZ696 in Heart Failure with Preserved Ejection Fraction The Prospective comparison of ARNI with ARB on Management Of heart failure with preserved ejection
More informationMetoprolol CR/XL in Female Patients With Heart Failure
Metoprolol CR/XL in Female Patients With Heart Failure Analysis of the Experience in Metoprolol Extended-Release Randomized Intervention Trial in Heart Failure (MERIT-HF) Jalal K. Ghali, MD; Ileana L.
More informationFOCUS ON CARDIOVASCULAR DISEASE
The Consequences of Vitamin D Deficiency: FOCUS ON CARDIOVASCULAR DISEASE Vitamin D deficiency is a global health problem. With all the medical advances of the century, vitamin D deficiency is still epidemic.
More informationCombination therapy Giuseppe M.C. Rosano, MD, PhD, MSc, FESC, FHFA St George s Hospitals NHS Trust University of London
Combination therapy Giuseppe M.C. Rosano, MD, PhD, MSc, FESC, FHFA St George s Hospitals NHS Trust University of London KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email:
More informationThe Who, How and When of Advanced Heart Failure Therapies. Disclosures. What is Advanced Heart Failure?
The Who, How and When of Advanced Heart Failure Therapies 9 th Annual Dartmouth Conference on Advances in Heart Failure Therapies Dartmouth-Hitchcock Medical Center Lebanon, NH May 20, 2013 Joseph G. Rogers,
More informationHeart Failure Treatments
Heart Failure Treatments Past & Present www.philippelefevre.com Background Background Chronic heart failure Drugs Mechanical Electrical Background Chronic heart failure Drugs Mechanical Electrical Sudden
More informationDiagnosis is it really Heart Failure?
ESC Congress Munich - 25-29 August 2012 Heart Failure with Preserved Ejection Fraction From Bench to Bedside Diagnosis is it really Heart Failure? Prof. Burkert Pieske Department of Cardiology Med.University
More informationBeyond ACE-inhibitors for Heart Failure. Jacob Townsend, MD NCVH Birmingham 2015
Beyond ACE-inhibitors for Heart Failure Jacob Townsend, MD NCVH Birmingham 2015 % Decrease in Mortality Current Therapy HFrEF 0% Angiotensin receptor blocker ACE inhibitor Beta blocker Mineralocorticoid
More informationHFpEF. April 26, 2018
HFpEF April 26, 2018 (J Am Coll Cardiol 2017;70:2476 86) HFpEF 50% or more (40-71%) of patients with CHF have preserved LV systolic function. HFpEF is an increasingly frequent hospital discharge. Outcomes
More informationInnovation therapy in Heart Failure
Innovation therapy in Heart Failure P. Laothavorn September 2015 Topics of discussion Basic Knowledge about heart failure Standard therapy New emerging therapy References: standard Therapy in Heart Failure
More informationInfluence of Baseline and Worsening Renal Function on Efficacy of Spironolactone in Patients With Severe Heart Failure
Journal of the American College of Cardiology Vol. 60, No. 20, 2012 2012 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.07.048
More informationGALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS
GALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS Table of Contents List of authors pag 2 Supplemental figure I pag 3 Supplemental figure II pag 4 Supplemental
More informationDiastolic Function. Rick Nishimura Leighton Professor of CV Diseases Mayo Clinic No Disclosures
Diastolic Function Rick Nishimura Leighton Professor of CV Diseases Mayo Clinic No Disclosures Heart = Pump Heart Failure Systolic Dysfunction Diastolic Dysfunction Diastole is a complex sequence of multiple
More informationCopeptin in heart failure: Associations with clinical characteristics and prognosis
Copeptin in heart failure: Associations with clinical characteristics and prognosis D. Berliner, N. Deubner, W. Fenske, S. Brenner, G. Güder, B. Allolio, R. Jahns, G. Ertl, CE. Angermann, S. Störk for
More informationCKD Satellite Symposium
CKD Satellite Symposium Recommended Therapy by Heart Failure Stage AHA/ACC Task Force on Practice Guideline 2001 Natural History of Heart Failure Patients surviving % Mechanism of death Sudden death 40%
More informationΦαρμακευτική θεραπεία της μετεμφραγματικής καρδιακής ανεπάρκειας. Α. Καραβίδας Υπεύθυνος ιατρείου καρδιακής ανεπάρκειας Γ.Ν.Α Γ.
Φαρμακευτική θεραπεία της μετεμφραγματικής καρδιακής ανεπάρκειας Α. Καραβίδας Υπεύθυνος ιατρείου καρδιακής ανεπάρκειας Γ.Ν.Α Γ.Γεννηματάς Clinical Trials on Fibrinolysis N = 61.41 AMI pts, ( GUSTO I, GUSTOIIb,
More informationHeart Failure Guidelines For your Daily Practice
Heart Failure Guidelines For your Daily Practice Juan M. Aranda, Jr., MD, FACC, FHFSA Professor of Medicine Director of Heart Failure and Cardiac Transplantation University of Florida College of Medicine
More informationFaiez Zannad. Institut Lorrain du Coeur et des Vaisseaux. CIC - Inserm
Faiez Zannad Institut Lorrain du Coeur et des Vaisseaux CIC - Inserm Disclosure Faiez Zannad Grants BG Medicine, Roche Diagnostics. Consultant/Steering committees/event committees/ Data safety Monitoring
More informationΒΙΟΔΕΙΚΤΕΣ ΣΤΗΝ ΚΑΡΔΙΑΚΗ ΑΝΕΠΑΡΚΕΙΑ. ΔΗΜΗΤΡΙΟΣ ΤΟΥΣΟΥΛΗΣ Καθηγητής Καρδιολογίας
ΕΘΝΙΚΟ ΚΑΙ ΚΑΠΟΔΙΣΤΡΙΑΚΟ ΠΑΝΕΠΙΣΤΗΜΙΟ ΑΘΗΝΩΝ ΙΑΤΡΙΚΗ ΣΧΟΛΗ Ά ΚΑΡΔΙΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ Διευθυντής: Καθηγητής Δημήτριος Τούσουλης ΒΙΟΔΕΙΚΤΕΣ ΣΤΗΝ ΚΑΡΔΙΑΚΗ ΑΝΕΠΑΡΚΕΙΑ ΔΗΜΗΤΡΙΟΣ ΤΟΥΣΟΥΛΗΣ Καθηγητής Καρδιολογίας
More informationAntihypertensive Trial Design ALLHAT
1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes
More informationDespite declining age-adjusted incidence and mortality
Sex Differences in the Prognosis of Congestive Heart Failure Results From the Cardiac Insufficiency Bisoprolol Study (CIBIS II) Tabassome Simon, MD; Murielle Mary-Krause, PhD; Christian Funck-Brentano,
More informationHeart Failure in Women: Dr Goh Ping Ping Cardiologist Asian Heart & Vascular Centre
Heart Failure in Women: More than EF? Dr Goh Ping Ping Cardiologist Asian Heart & Vascular Centre Overview Review pathophysiology as it relates to diagnosis and management Rational approach to workup:
More informationSUPPLEMENTAL MATERIAL
SUPPLEMENTAL MATERIAL Clinical perspective It was recently discovered that small RNAs, called micrornas, circulate freely and stably in human plasma. This finding has sparked interest in the potential
More informationUpdate on pharmacological treatment of heart failure. Aldo Pietro Maggioni, MD, FESC ANMCO Research Center Firenze, Italy
Update on pharmacological treatment of heart failure Aldo Pietro Maggioni, MD, FESC ANMCO Research Center Firenze, Italy Presenter Disclosures Dr. Maggioni : Serving in Committees of studies sponsored
More informationIncidence. 4.8 million in the United States. 400,000 new cases/year. 20 million patients with asymptomatic LV dysfunction
Heart Failure Diagnosis According to the Working Group in Heart Failure, CHF is a syndrome where the diagnosis has the following essential components: A combination of: Symptoms, typically breathlessness
More informationRikshospitalet, University of Oslo
Rikshospitalet, University of Oslo Preventing heart failure by preventing coronary artery disease progression European Society of Cardiology Dyslipidemia 29.08.2010 Objectives The trends in cardiovascular
More informationLXIV: DRUGS: 4. RAS BLOCKADE
LXIV: DRUGS: 4. RAS BLOCKADE ACE Inhibitors Components of RAS Actions of Angiotensin i II Indications for ACEIs Contraindications RAS blockade in hypertension RAS blockade in CAD RAS blockade in HF Limitations
More informationHeart failure (HF) is a clinical syndrome associated with significant
review efficacy and safety of mineralocorticoid receptor antagonist therapy in heart failure with reduced ejection fraction Arden R Barry BSc BSc(Pharm) PharmD ACPR 1, Sheri L Koshman BScPharm PharmD ACPR
More informationHeart Failure Update John Coyle, M.D.
Heart Failure Update 2011 John Coyle, M.D. Causes of Heart Failure Anderson,B.Am Heart J 1993;126:632-40 It It is now well-established that at least one-half of the patients presenting with symptoms and
More informationMineralocorticoid receptor antagonists (MRAs) have. Original Article
Original Article Incidence, Predictors, and Outcomes Related to Hypo- and Hyperkalemia in Patients With Severe Heart Failure Treated With a Mineralocorticoid Receptor Antagonist Orly Vardeny, PharmD, MS;
More informationEffects of heart rate reduction with ivabradine on left ventricular remodeling and function:
Systolic Heart failure treatment with the If inhibitor ivabradine Trial Effects of heart rate reduction with ivabradine on left ventricular remodeling and function: results of the SHIFT echocardiography
More informationReplicating Randomised Trials of Treatments in Observational Settings Using Propensity Scores Fisher s Aphorisms
Replicating Randomised Trials of Treatments in Observational Settings Using Propensity Scores Fisher s Aphorisms Nick Freemantle PhD Professor of Clinical Epidemiology & Biostatistics Assessing Causation
More informationACE inhibitors: still the gold standard?
ACE inhibitors: still the gold standard? Session: Twenty-five years after CONSENSUS What have we learnt about the RAAS in heart failure? Lars Køber, MD, D.Sci Department of Cardiology Rigshospitalet University
More informationA patient with decompensated HF
A patient with decompensated HF Professor Michel KOMAJDA University Pierre & Marie Curie Pitie Salpetriere Hospital Department of Cardiology Paris (France) Declaration Of Interest 2010 Speaker : Servier,
More informationNew evidences in heart failure: the GISSI-HF trial. Aldo P Maggioni, MD ANMCO Research Center Firenze, Italy
New evidences in heart failure: the GISSI-HF trial Aldo P Maggioni, MD ANMCO Research Center Firenze, Italy % Improving survival in chronic HF and LV systolic dysfunction: 1 year all-cause mortality 20
More informationEffects of spironolactone and losartan on the early neovascularization of acute myocardial infarction
978 Effects of spironolactone and losartan on the early neovascularization of acute myocardial infarction YAN LIU 1 and KUNSHEN LIU 2 1 Department of Geriatrics, The First Hospital of Shijiazhuang City,
More informationTreatment of Heart Failure: Current Recommendation Waiz A
Treatment of Heart Failure: Current Recommendation Waiz A The impaired left ventricular emptying that characterizes heart failure may result from a variety of cardiac diseases, including myocardial ischaemia
More informationDialysis-Dependent Cardiomyopathy Patients Demonstrate Poor Survival Despite Reverse Remodeling With Cardiac Resynchronization Therapy
Dialysis-Dependent Cardiomyopathy Patients Demonstrate Poor Survival Despite Reverse Remodeling With Cardiac Resynchronization Therapy Evan Adelstein, MD, FHRS John Gorcsan III, MD Samir Saba, MD, FHRS
More informationST2 in Heart Failure. ST2 as a Cardiovascular Biomarker. Competitive Model of ST2/IL-33 Signaling. ST2 and IL-33: Cardioprotective
ST2 as a Cardiovascular Biomarker Lori B. Daniels, MD, MAS, FACC Professor of Medicine Director, Coronary Care Unit University of California, San Diego ST2 and IL-33: Cardioprotective ST2: member of the
More informationWhy to use digoxin in heart failure?
Why to use digoxin in heart failure? Yves Juillière, Cardiology, ILCV, CHU Nancy-Brabois, France Digitalis purpurea Representation of the extracellular loops and the transmembrane domain regions of the
More informationEffects of Kidney Disease on Cardiovascular Morbidity and Mortality
Effects of Kidney Disease on Cardiovascular Morbidity and Mortality Joachim H. Ix, MD, MAS Assistant Professor in Residence Division of Nephrology University of California San Diego, and Veterans Affairs
More informationSevere left ventricular dysfunction and valvular heart disease: should we operate?
Severe left ventricular dysfunction and valvular heart disease: should we operate? Laurie SOULAT DUFOUR Hôpital Saint Antoine Service de cardiologie Pr A. COHEN JESFC 16 janvier 2016 Disclosure : No conflict
More informationClinical Review Criteria Galectin-3 Blood Assay Test
Clinical Review Criteria Galectin-3 Blood Assay Test Kaiser Foundation Health Plan of Washington NOTICE: Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options,
More informationOptimal Adrenergic Blockades in Heart Failure. Jae-Joong Kim MD, PhD Asan Medical Center, University of Ulsan, Seoul, Korea
Optimal Adrenergic Blockades in Heart Failure Jae-Joong Kim MD, PhD Asan Medical Center, University of Ulsan, Seoul, Korea Contents Harmful effects of adrenergic system in heart failure Clinical studies
More informationThe Cardiovascular System and Aging- Is it Built to Fail?
The Cardiovascular System and Aging- Is it Built to Fail? Francis G. Spinale, MD, PhD Professor of Surgery and Cell Biology and Anatomy University of South Carolina School of Medicine Veterans Affairs
More informationThe Failing Heart in Primary Care
The Failing Heart in Primary Care Hamid Ikram How fares the Heart Failure Epidemic? 4357 patients, 57% women, mean age 74 years HFSA 2010 Practice Guideline (3.1) Heart Failure Prevention A careful and
More informationChapter 10. Learning Objectives. Learning Objectives 9/11/2012. Congestive Heart Failure
Chapter 10 Congestive Heart Failure Learning Objectives Explain concept of polypharmacy in treatment of congestive heart failure Explain function of diuretics Learning Objectives Discuss drugs used for
More informationRAS Blockade Across the CV Continuum
A Summary of Recent International Meetings RAS Blockade Across the CV Continuum Copyright New Evidence Presented at the 2009 Congress of the European Society of Cardiology (August 29-September 2, Barcelona)
More informationEplerenone and Atrial Fibrillation in Mild Systolic Heart Failure
Journal of the American College of Cardiology Vol. 59, No. 18, 2012 2012 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2011.11.063
More informationClinical Investigations
Clinical Investigations Predictors of 30-Day Readmission in Patients Hospitalized With Decompensated Heart Failure Address for correspondence: Gian M. Novaro, MD, Department of Cardiology, Cleveland Clinic
More information